Eli Lilly announces Phase 2 trial of lepodisiran met primary endpoint
Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...
Hemophilia News Today3h
Fitusiran, now Qfitlia, approved by FDA for hemophilia A, B patients
The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...
The Mirror6d
Two Premier League clubs in transfer battle with RB Leipzig for England U21 starlet
A number of Premier League clubs have an eye on Tyler Dibling, but they face a battle. Tottenham Hotspur and Manchester City might have the Southampton starlet in their sights, but the teenager ...
C&EN6d
Expression of Human β3GalT5–1 in Insect Cells as Active Glycoforms for the Efficient Synthesis of Cancer-Associated Globo-Series Glycans
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. The globo-series glycosphingolipids (GSLs) are unique glycolipids exclusively ...
C&EN6d
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States ...